Hyperthermia Systems segmentation by application reveals four primary demand drivers. Cancer treatment remains the dominant segment, accounting for roughly 55 % of total revenue, driven by clinical protocols that combine hyperthermia with radiotherapy or chemotherapy for breast, cervical, and sarcoma tumors. The dermatological disorders segment contributes about 25 % of market size, reflecting the use of localized heating for conditions such as psoriasis and actinic keratosis, where precise temperature control improves therapeutic outcomes. Neurological disorders represent an emerging niche, currently 15 % of the market, with investigational use in glioblastoma and Alzheimer's disease where blood‑brain barrier modulation is sought. The residual 5 % falls under other applications such as veterinary oncology and cosmetic skin tightening, which, while small, indicate diversification potential. Together, these application categories structure the overall Hyperthermia Systems market, guiding R&D allocation and geographic sales strategies. Forecasts project a compound annual growth rate of 7 % through 2032, with oncology driving the bulk of incremental volume as new combination protocols gain regulatory approval.
